Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

How do BRAFV600E and TERT promoter mutations interact with the ATA and TNM staging systems in thyroid cancer?

Frontiers in endocrinology - 1 Jan 2023

Mukhtar Noha, Alhamoudi Kheloud, Alswailem Meshael, Alhindi Hindi, Murugan Avaniyapuram Kannan, Alghamdi Balgees, Alzahrani Ali S

Abstract excerpt

Context: The American Thyroid Association risk stratification (ATA) and the American Joint Committee on Cancer Tumor Node Metastases (TNM) predict recurrence and mortality of differentiated thyroid cancer (DTC). BRAFV600E and TERT promoter mutations have been shown to correlate with the histopathological features and outcome of DTC. Our objectives were to study the correlation of these molecular markers with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Telomerase
Share to Adenocarcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Papillary

Share to Neoplasm Staging

Share to Promoter Regions, Genetic

Share to Proto-Oncogene Proteins B-raf

Share to Thyroid Cancer, Papillary

Share to Thyroid Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 37859987
DOI: 10.3389/fendo.2023.1270796
PMCID: PMC10582750

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

How do BRAFV600E and TERT promoter mutations interact with the ATA and TNM staging systems in thyroid cancer?PMID 37859987Read ↗

Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients.Semantic proximity Read ↗

TERT promoter mutations and long-term survival in patients with thyroid cancer.Semantic proximity Read ↗

Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis.Semantic proximity Read ↗

Risk-stratified Distant Metastatic Thyroid Cancer with Clinicopathological Factors and BRAF/TERT Promoter Mutations.Semantic proximity Read ↗

BRAF and TERT promoter mutations: clinical application in thyroid cancer.Semantic proximity Read ↗

Disease-Specific and Histological Outcomes of Preoperative TERT Promoter Mutation Detected in Isolation or in Combination with Other Mutations in Thyroid Neoplasms.Semantic proximity Read ↗

Prognostic significance of TERT promoter and BRAF mutations in TIR-4 and TIR-5 thyroid cytologySemantic proximity Read ↗

The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: A systematic review and meta-analysis.Semantic proximity Read ↗

The role of TERT promoter mutations in postoperative and preoperative diagnosis and prognosis in thyroid cancer.Semantic proximity Read ↗

Impact of BRAF V600E and TERT Promoter Mutations on Response to Therapy in Papillary Thyroid CancerSemantic proximity Read ↗

TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.Semantic proximity Read ↗

Refining Dynamic Risk Stratification and Prognostic Groups for Differentiated Thyroid Cancer With TERT Promoter Mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.